Our new forms of insulin, based on novel protein designs and formulations, will enable insulin-dependent type 1 and type 2 diabetes patients to achieve improved glycemic control and quality of life, while reducing the costs of diabetes-related illnesses to the healthcare system. Our team includes the leading scientist in insulin biochemistry (Professor at Indiana University School of Medicine), the co-inventor of the first commercial insulin analog, experienced drug/device dealmakers, and a world-class scientific staff. Our clinical advisory board includes some of the foremost endocrinologists in the country. We plan to be in human testing on our lead compound in 2023. Target product profiles for which we have viable candidates include: - Ultra-stable insulins that do not need to be refrigerated (especially useful in the developing world) - Ultra-rapid absorbing insulins required for artificial pancreas systems - Ultra-concentrated insulins for miniaturized insulin pumps and for insulin-resistant patients